Signal transduction pathways and transcriptional mechanisms as targets for prevention of emergence of multidrug resistance in human cancer cells

Current Drug Targets

Volumn 2, Issue 1, 2001, Pages 57-77

  Shtil, A A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CALPHOSTIN C; CHELERYTHRINE; CYTARABINE; CYTOTOXIC AGENT; GLYCOPROTEIN P; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MACROGOL STEARATE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; PHORBOL 13 ACETATE 12 MYRISTATE; POLYAMIDE; PROTEIN KINASE C; PYRROLIDINE DITHIOCARBAMATE; SALICYLATE SODIUM; TOSYLPHENYLALANYL CHLOROMETHYL KETONE; TRABECTEDIN;

ARTICLE; CANCER CELL; CANCER PATIENT; CANCER RECURRENCE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MINIMAL RESIDUAL DISEASE; MULTIDRUG RESISTANCE; PHENOTYPE; SIGNAL TRANSDUCTION; STIMULUS RESPONSE; STRESS; TRANSCRIPTION REGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; DRUG RESISTANCE, MULTIPLE; GENES, MDR; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 0035031007     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389450013348957     Document Type: Article

References (159)

1. Active outward transport of daunorubicin in resistant Ehrlich ascites tumor cells
2. Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells
3. Genetic and biochemical characterization of multidrug resistance
4. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
5. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines
6. ATP-binding properties of P-glycoprotein from multidrug-resistant KB cells
7. Purification of the 170- to 180-kilodalton membrane glycoprotein associated with multidrug resistance. 170- to 180-kilodalton membrane glycoprotein is an ATPase
8. Expression of the human multidrug resistance cDNA in insect cells generates a high activity of drug-stimulated membrane ATPase
9. P-glycoprotein function involves conformational transitions detectable by differential immunoreactivity
10. Structure of the multidrug resistance P-glycoprotein
11. Chromosomal localization in normal human cells and CHO cells of a sequence derived from P-glycoprotein (PGY1)
12. Localization of multidrug resistance-associated DNA sequences to human chromosome 7
13. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells
14. Multidrug resistance of DNA-mediated transformants is linked to transfer of the human mdr1 gene
15. Expression of a full-length cDNA for the human MDR1 gene confers resistance to colchicine, doxorubicin, and vinblastine
16. Reversal of multidrug resistance by calcium channel blockers and other agents
17. Expression of the multidrug resistance gene in human cancer
18. Multidrug resistance gene expression in childhood medulloblastoma: Correlation with clinical outcome and DNA ploidy in 29 patients
19. Prognostic relevance of P-glycoprotein expression in breast cancer
20. Cytogenetics and P-glycoprotein (Pgp) are independent predictors of treatment outcome in acute myeloid leukemia (AML)
21. Expression of the MDR1 gene product P-glycoprotein in childhood neuroblastoma
22. The prognostic value of MDR1 gene expression in primary untreated neuroblastoma
23. Adult biphenotypic acute leukaemia: An entity with poor prognosis which is related to unfavourable cytogenetics and P-glycoprotein over-expression
24. Prognostic value of P-glycoprotein and leukocyte differentiation antigens in chronic myeloid leukemia
25. Multidrug resistance in aggressive lymphoproliferative disorders of T and natural-killer origin
26. Drug resistance and sensitivity of germ cell testicular tumors: Evaluation of clinical relevance of MDR1/Pgp, p53, and metallothionein (MT) proteins
27. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival
28. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphoid leukaemias: Biological and clinical implications
29. Studies of some mechanisms of drug resistance in chronic myeloid leukemia (CML)
30. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells
31. Regulation of MDR1 gene expression: Emerging concepts
32. Multidrug resistance - A multiplex phenomenon
33. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions
34. Multidrug resistance: Molecular and clinical aspects
35. Negative regulation of MDR1 promoter activity in MCF-7, but not in multidrug resistant MCF-7/Adr, cells by cross-coupled NFκB/p65 and c-Fos transcription factors and their interaction with the CAAT region
36. Recent progress in P-glycoprotein research
37. Identification and characterization of the MDR1 promoter-enhancing factor 1 (MEF1) in the multidrug resistant HL60/VCR human acute myeloid leukemia cell line
38. Multidrug resistance-associated protein subfamily transporters and drug resistance
39. Novel mechanisms of drug resistance in leukemia
40. Expression of a drug resistance gene in human neuroblastoma cell lines: Modulation by retinoic acid-induced differentiation
41. Modulation of the expression of a multidrug resistance gene (mdr1/P-glycoprotein) by differentiating agents
42. Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells
43. Enhanced expression of the human multidrug resistance 1 gene in response to UV light irradiation
44. Protein kinase C: Structure, function, and regulation
45. Lipid mediators and protein kinase C for intracellular signaling
46. Activation of MDR1 (P-glycoprotein) gene expression in human cells by protein kinase C agonists
47. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs
48. Use of fluorescent dyes as molecular probes for the study of multidrug resistance
49. Dissection of signal transduction pathways regulating the induction of MDR1 gene expression in human leukemia cells
50. Method for preventing multidrug resistance in cancer cells
51. 60 Hz electric fields inhibit protein kinase C activity and multidrug resistance gene (MDR1) upregulation
52. Phorbol ester induced MDR1 expression in K562 cells occurs independently of mitogen-activated protein kinase signaling pathways
53. Selective inhibition of protein kinase C isoenzymes by the indolocarbazole Gö 6976
54. Atypical isoforms of PKC and insulin secretion from pancreatic beta-cells: Evidence using Gö 6976 and Ro 31-8220 as PKC inhibitors
55. Protein kinase C targeting in antineoplastic treatment strategies
56. Regulation of expression of the DNA repair gene O6-methylguanine-DNA methyltransferase via protein kinase C-mediated signaling
57. Regulation of MCL1 through a serum response factor/Elk-1-mediated mechanism links expression of a viability-promoting member of the BCL2 family to the induction of hematopoietic cell differentiation
58. Activation of the LRP (lung resistance-related protein) gene by short-term exposure of human leukemia cells to phorbol ester and cytarabine
59. Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating death signals
60. 12-O-tetradecanoylphorbol 13-acetate-induced apoptosis in LNCaP cells is mediated through ceramide synthase
61. Ceramide inhibits protein kinase C (PKC) activity and activates the MDR1 gene in human leukemia cells: Evidence for a PKC-independent mechanism of up-regulation of multidrug resistance
62. Functions of sphingolipids and sphingolipid breakdown products in cellular regulation
63. Inhibition of cytarabine-induced MDR1 (P-glycoprotein) gene activation in human tumor cells by fatty acid-PEG-fatty acid diesters, novel inhibitors of P-glycoprotein function
64. How NFκB is activated: The role of IκB kinase (IKK) complex
65. NF-κB as a primary regulator of the stress response
66. Signal-induced site-specific phosphorylation targets IκBα to the ubiquitin-proteasome pathway
67. Control of IκBα proteolysis by site-specific, signal-induced phosphorylation
68. Mapping of the inducible IκBα phosphorylation sites that signal its ubiquitination and degradation
69. Stimulation-dependent IκBα phosphorylation marks the NF-κB inhibitor for degradation via the ubiquitin-proteasome pathway
70. Signal-induced degradation of IκB requires site-specific ubiquitination
71. The ubiquitin system
72. Activation of interleukin-6 gene expression through the NFκB transcription factor
73. Dithiocarbamates as potent inhibitors of nuclear factor κB activation in intact cells
74. Pyrrolidine dithiocarbamate inhibits NF-κB mobilization and TNF production in human monocytes
75. Inhibition of NFκB by sodium salicylate and aspirin
76. A proteasome inhibitor prevents activation of NF-κB and stabilizes a newly phosphorylated form of I κB-α that is bound to NF-κB
77. Chloromethyl ketones block induction of nitric oxide synthase in murine macrophages by preventing activation of nuclear factor-κB
78. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β
79. Regulation of RANTES chemokine gene expression requires cooperativity between NF-κB and IFN-regulatory factor transcription factors
80. Up-regulation of multidrug resistance P-glycoprotein via nuclear factor -κB activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis
81. IEX-1L, an apoptosis inhibitor involved in NFκB-mediated cell survival
82. NF-κB inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells
83. NF-κB inhibits apoptosis in murine mammary epithelia
84. NF-κB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events
85. NF-κB and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene
86. Identification of 5′ and 3′ sequences involved in the regulation of transcription of the human mdr1 gene in vivo
87. The human multidrug resistance (MDR1) gene: cDNA cloning and transcription initiation
88. Structure and expression of the human MDR (P-glycoprotein) gene family
89. 12-O-tetradecanoylphorbol-13-acetate activation of the MDR1 promoter is mediated by EGR1
90. Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y
91. The Wilms' tumor suppressor, WT1, inhibits 12-O-tetradecanoylphorbol-13-acetate activation of the multidrug resistance-1 promoter
92. Activation of MDR1 transcription by ATRA in neuroblastoma cells is mediated by a complex interplay of multiple Sp family members
93. Control of histone modifications
94. The language of covalent histone modifications
95. Histone acetylation and transcriptional regulatory mechanisms
96. Promoter-region hypermethylation and gene silencing in human cancer
97. A bird's eye view of global methylation
98. Association of 5′CpG demethylation and altered chromatin structure in the promoter region with transcriptional activation of the multidrug resistance 1 gene in human cancer cells
99. Hypomethylation status of CpG site at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias
100. Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance
101. Demethylation of the human MDR1 5′ region accompanies activation of P-glycoprotein expression in a HL60 multidrug resistant subline
102. Methylation analysis of the human multidrug resistance 1 gene in normal and leukemic hematopoietic cells
103. Identification and characterization of a family of mammalian methyl-CpG binding proteins
104. Mammalian methyltransferases and methyl-CpG-binding domains: Proteins involved in DNA methylation
105. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer
106. Transcriptional regulation of MDR genes
107. Protein-protein interactions as critical determinants of regulated initiation and termination of transcription
108. Isolation and sequence of the promoter region of the human multidrug resistance (P-glycoprotein) gene
109. Differential utilization of multiple transcription start points accompanies the overexpression of the P-glycoprotein-encoding gene in Chinese hamster lung cells
110. Regulation of inducible and tissue-specific gene expression
111. In vitro antitumor activity of the novel marine agent, ecteinascidin 743 (ET743, NSC-648766) against human tumors explanted from patients
112. Ecteinascidin 743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts
113. Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743
114. Enantioselective synthesis of saframycin A and evaluation of antitumor activity relative to ecteinascidin/saframycin hybrids
115. A new, more efficient, and effective process for synthesis of a key pentacyclic intermediate for production of ecteinascidin and phthalascidin antitumor agents
116. Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosaframycin B
117. Molecular basis for the DNA sequence selectivity of ecteinascidin 736 and 743: Evidence for the dominant role of direct readout via hydrogen bonding
118. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the caribbean tunicate Ecteinascidia turbinata
119. Ecteinascidin 743: A minor groove alkylator that bends DNA toward the major groove
120. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743
121. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation
122. Molecular approaches to achieving control of gene expression by drug intervention at the transcriptional level
123. A structural basis for recognition of A.T and T.A base pairs in the minor groove of B-DNA
124. Targeting the minor groove of DNA
125. Recognition of the four Watson-Crick base pairs in the DNA minor groove by synthetic ligands
126. Inhibition of RNA polymerase II transcription in human cells by synthetic DNA-binding ligands
127. Targeting the Ets binding site of the HER2/neu promoter with pyrrole-imidazole polyamides
128. Control of gene expression by oligodeoxynucleotides covalently linked to intercalating agents and nucleic acid-cleaving reagents
129. Recognition of 16 base pairs in the minor groove of DNA by a pyrrole-imidazole polyamide dimer
130. Generality of a functional initiator consensus sequence
131. Synthesis and biological activity and DNA damaging agents that form decoy binding sites for the estrogen receptor
132. Glucocorticoids repress transcription of the hamster class I P-glycoprotein promoter through an activator occlusion mechanism
133. Retinoids in neuroblastoma therapy: Distinct biological properties of 9-cis- and all-trans-retinoic acid
134. New chemotherapeutic strategies for soft tissue sarcomas
135. Suppression of rat tumorigenesis by 25-hydroxycholesterol and all-trans-retinoic acid: Differentiation therapy for hepatocellular carcinoma
136. Valproic acid for treatment of pediatric malignant glioma
137. Reverse transformation of multidrug-resistant cells
138. Characterization in vitro and in vivo of progressively Adriamycin-resistant B16-BL6 mouse melanoma cells
139. Correlations between multidrug resistance and differentiation in the mouse erythroleukosis
140. Alterations in melanin synthesis in human melanoma cells selected in vitro for multidrug resistance
141. Frequency of metastasis in Syrian hamster tumor cells selected for low levels of 'typical' multidrug resistance
142. The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells
143. Caveolins, liquid-ordered domains, and signal transduction
144. Caveolins, a family of scaffolding proteins for organizing 'preassembled signaling complexes' at the plasma membrane
145. Caveolin 1-mediated regulation of receptor tyrosine kinase-associated phosphatidylinositol 3-kinase activity by ceramide
146. Upregulation of caveolae and caveolar constituents in multidrug-resistant cancer cells
147. Changes in membrane microdomains and caveolae constituents in multidrug-resistant cancer cells
148. P-glycoprotein is localized in caveolae in resistant cells and in brain capillaries
149. Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant A549 cells
150. Two sterol regulatory element-like sequences mediate upregulation of caveolin gene expression in response to low density lipoprotein free cholesterol
151. Insulin-like growth factor-II, phosphatidylinositol-3-kinase, nuclear factor-kappa B and inducible nitric-oxide synthase define a common myogenic signaling pathway
152. Regulation of MDR1 gene expression and P-glycoprotein function in cultured melanoma and hepatoma cells
153. Accumulation of glucosylceramide in multidrug-resistant cancer cells
154. Glucosylceramide: A marker for multiple-drug resistant cancers
155. Overexpression of the MDR1 gene is associated with a decreased mitochondrial transmembrane potential in K562 human leukemia cells selected for P-glycoprotein-mediated multidrug resistance
156. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin
157. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis
158. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death
159. P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway